Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) patients who are resistant to TKI therapy. Here, EGFR is linked to non-small cell lung carcinoma.